Caffeine is widely used across pharmaceutical formulations from analgesics to CNS stimulants. Its familiarity often leads to a simple assumption: that it behaves predictably.

In reality, caffeine API is more sensitive than it appears.

For formulators, especially during reformulation cycles, certain underlying characteristics of caffeine can directly influence stability, performance, and regulatory flexibility. These are not always visible during early development but tend to surface later, when timelines are tighter and changes are harder to implement.

Here are three aspects that are often overlooked, but critical to get right.

Form-II Stability: Ensuring Consistency Over Shelf-Life

Caffeine exists in multiple polymorphic forms. Among these, Form-II is the thermodynamically stable form under standard conditions.

Why does this matter?

Because polymorphic stability directly impacts how the API behaves over time. When caffeine is not consistently maintained in its stable form, there is a possibility of solid-state transitions during storage. 

This can lead to:

• Variations in solubility
• Changes in dissolution behaviour
• Physical instability within the formulation
• Drift in analytical results over time

These effects are not always immediate. A formulation may meet all specifications at release, only to show variability during stability studies.

Ensuring the use of a consistently controlled Form-II caffeine API helps maintain alignment between development data and real-world product performance reducing the risk of late-stage surprises.

d90 Particle Size: A Critical Parameter in Liquid and Semi-Solid Systems

Particle size distribution plays a significant role in how caffeine performs within a formulation. In particular, d90 particle size which represents the upper range of particle distribution has a direct impact on both processing and product stability.

In liquid formulations, this influences:

Dissolution and Bioavailability

• Smaller particles increase surface area and dissolve faster
• Overly fine distributions can lead to supersaturation and recrystallisation

Suspension Stability

• Larger or inconsistent particles may settle faster
• Poor control can lead to caking and redispersion challenges
• Dose uniformity may be affected over time

Manufacturing Efficiency

• Fine particles may impact filtration efficiency
• Coarser particles may require longer dissolution times

The objective is not to minimise particle size, but to control and standardise distribution in line with formulation requirements.

An optimised and consistent d90 specification helps ensure predictable behaviour across batches both during processing and throughout shelf-life.

Pharmacopoeia Coverage- Preparing for Regulatory Flexibility

Caffeine API is referenced across multiple global pharmacopoeias, including:

• European Pharmacopoeia (EP)
• British Pharmacopoeia (BP)
• United States Pharmacopeia (USP)
• Indian Pharmacopoeia (IP)
• Japanese Pharmacopoeia (JP)

While this reflects its global acceptance, it also introduces complexity.

Differences may exist across these monographs in terms of:

• Impurity limits
• Analytical methodologies
• Residual solvent specifications
• Identification criteria

During development, formulations are often aligned with a primary pharmacopoeia. But challenges arise when:

• Expanding into new regulatory markets
• Working with international partners
• Responding to multi-region compliance requirements

At this stage, gaps in pharmacopoeial alignment can lead to additional validation work, delayed approvals, or the need for API requalification.

Selecting a caffeine API that is compliant with multiple pharmacopoeial standards simultaneously provides greater flexibility ensuring readiness for evolving regulatory and commercial requirements.

A More Considered Approach to a Familiar API

Caffeine may be widely used, but it is not without complexity.

Its performance is influenced by:

• Solid-state characteristics
• Particle engineering
• Regulatory alignment

Each of these factors plays a role in how a formulation behaves not just at release, but throughout its lifecycle.

For formulators, especially those entering a reformulation phase, a more detailed evaluation of caffeine API can help avoid downstream challenges and ensure consistent product performance.

At Farmson Basic Drugs, Caffeine API manufacturing is approached with a focus on consistency, control, and global compliance.

• Controlled crystallisation processes help ensure stable polymorphic form
• Particle size distribution is optimised for formulation-specific requirements
• Compliance across major pharmacopoeias supports global market readiness

This integrated approach helps ensure that caffeine performs as expected across batches, across formulations, and across markets.

What Formulators Should Evaluate Before the Next Reformulation Cycle

A few key questions can make a meaningful difference:

• Is the caffeine API consistently maintained in its stable polymorphic form?
• How tightly is the particle size distribution, especially d90, controlled?
• Does the API support multi-pharmacopoeial compliance without additional adjustments?

Addressing these early helps reduce variability later.

How We Can Support Your Formulation Needs

At Farmson Basic Drugs, we not only work closely with formulation teams but also manufacture Caffeine API with a strong focus on consistency, control, and global compliance.

Our approach to caffeine manufacturing is built around:

• Controlled crystallisation to ensure stable polymorphic form
• Tight particle size distribution aligned with formulation requirements
• Compliance with multiple pharmacopoeial standards for global readiness

This allows us to support our partners not just with supply, but with reliable performance across development, scale-up, and commercial production.

Whether you are evaluating a new formulation or revisiting an existing one, our team can assist with:

• Technical insights on polymorphic stability
• Guidance on particle size optimisation
• Support for multi-pharmacopoeial documentation and alignment

If you have any questions or would like to discuss your specific requirements, our team would be happy to connect.